VIVUS (VVUS) Updates on Qsymia Ahead of JPMorgan Healthcare Conference
Tweet
Share
E-mail
VIVUS (Nasdaq: VVUS) is positive in early trading as the company filed what will be its presentation at the 32nd Annual JPMorgan Healthcare Conference.
Key points:
-- Over 36,000 pharmacies certified to dispense Qsymia as of December 31, 2013
-- Total prescriptions (TRx) since launch at about 403,000
-- Added 124,000 TRx in Q413
-- About 43 percent of U.S. Commercial Lives have access to Qsymia Tier 3 or higher as of December 31, 2013
-- Received two new U.S. patents (Nos. 8,580,298 and 8,580,299), extending coverage by nine years
More can be seen in VIVUS' 8-K filing here.
VIVUS will present on January 15, 2014, at 3:30pm PST.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- PTC Therapeutics (PTCT) Tops Q1 EPS by 9c, provides guidance
- L3Harris Technologies (LHX) Tops Q1 EPS by 15c; raises guidance
Create E-mail Alert Related Categories
Conference Calls, Corporate News, FDA, Guidance, SEC FilingsRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
